Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Following the pandemic, rates of violence in health care are still high.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, discusses the impact that early satiety can have on patients with myeloproliferative neoplasms and the role nurses play in helping patients manage this symptom.

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Investigators continue to explore new ways to manage colorectal cancer with a BRAF V600E mutation.

Every year, Huntsman Cancer Institute receives funding from the American Cancer Society to support the promising research of junior faculty.

Rachel Ceballos, PhD, has been appointed senior director of community outreach and engagement at Huntsman Cancer Institute at the University of Utah .

Neeraj Agarwal, MD, is now a distinguished member of the Fellows of the American Society of Clinical Oncology.

A study in the Journal of The National Cancer Institute Cancer Spectrum looked at chatbots and artificial intelligence (AI), as they become popular resources for cancer information.

A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.

Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.

Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.

The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.

The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.

Adding the immunotherapy to chemotherapy in the frontline setting may improve overall survival for patients with advanced biliary tract cancer.

Findings from biomarker tests for patients with chronic lymphocytic leukemia can help appropriately tailor therapy plans as well as identify patients eligible for clinical trials.

“Previously, this mutation has been undruggable, but this is now changing.”

Kristin Barber, FNP-BC, AOCNP, discusses ongoing phase 1 trials aimed at targeting mutations along the MAP kinase pathway.